$SNTA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in MADRIGAL PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in MADRIGAL PHARMACEUTICALS, INC.. Get notifications about new insider transactions in MADRIGAL PHARMACEUTICALS, INC. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 23 2021 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Option Exercise | A | 119.49 | 50,000 | 5,974,500 | 50,000 | |
Feb 23 2021 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Option Exercise | A | 119.49 | 32,000 | 3,823,680 | 32,000 | |
Feb 23 2021 | SNTA | MADRIGAL PHARMACEU ... | Sukhija Remy | Chief Commercial Of ... | Option Exercise | A | 119.49 | 24,000 | 2,867,760 | 24,000 | |
Feb 23 2021 | SNTA | MADRIGAL PHARMACEU ... | Lynch Brian Joseph | SVP and General Cou ... | Option Exercise | A | 119.49 | 32,000 | 3,823,680 | 32,000 | |
Feb 23 2021 | SNTA | MADRIGAL PHARMACEU ... | Taub Rebecca | See Remarks | Option Exercise | A | 119.49 | 44,000 | 5,257,560 | 44,000 | |
Dec 01 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 43,537 | 0 | 2,310,521 | 2.4 M to 2.3 M (-1.85 %) |
Dec 01 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 43,537 | 0 | 2,310,521 | 2.4 M to 2.3 M (-1.85 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 45,460 | 0 | 43,537 | 89 K to 43.5 K (-51.08 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 45,460 | 0 | 43,537 | 89 K to 43.5 K (-51.08 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 31,650 | 0 | 49,730 | 81.4 K to 49.7 K (-38.89 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 31,650 | 0 | 49,730 | 81.4 K to 49.7 K (-38.89 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 1,468,350 | 0 | 2,260,791 | 3.7 M to 2.3 M (-39.38 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 1,468,350 | 0 | 2,260,791 | 3.7 M to 2.3 M (-39.38 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 45,460 | 0 | 43,537 | 89 K to 43.5 K (-51.08 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 45,460 | 0 | 43,537 | 89 K to 43.5 K (-51.08 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 31,650 | 0 | 49,730 | 81.4 K to 49.7 K (-38.89 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 31,650 | 0 | 49,730 | 81.4 K to 49.7 K (-38.89 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 1,468,350 | 0 | 2,260,791 | 3.7 M to 2.3 M (-39.38 %) |
Sep 04 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 1,468,350 | 0 | 2,260,791 | 3.7 M to 2.3 M (-39.38 %) |
Aug 19 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | S | 107.64 | 7,303 | 786,095 | 42,875 | 50.2 K to 42.9 K (-14.55 %) |
Aug 19 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | S | 110.03 | 10,197 | 1,121,976 | 50,178 | 60.4 K to 50.2 K (-16.89 %) |
Aug 19 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | S | 110.73 | 12,500 | 1,384,125 | 60,375 | 72.9 K to 60.4 K (-17.15 %) |
Aug 19 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | S | 107.64 | 7,303 | 786,095 | 42,875 | 50.2 K to 42.9 K (-14.55 %) |
Aug 19 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | S | 110.03 | 10,197 | 1,121,976 | 50,178 | 60.4 K to 50.2 K (-16.89 %) |
Aug 19 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | S | 110.73 | 12,500 | 1,384,125 | 60,375 | 72.9 K to 60.4 K (-17.15 %) |
Aug 10 2020 | SNTA | MADRIGAL PHARMACEU ... | Lynch Brian Joseph | See Remarks | Option Exercise | A | 103.10 | 20,000 | 2,062,000 | 20,000 | |
Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | Daly James M | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | Gollust Keith R | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
Jun 18 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Option Exercise | A | 111.06 | 6,000 | 666,360 | 6,000 | |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 44,903 | 0 | 72,875 | 117.8 K to 72.9 K (-38.13 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 44,903 | 0 | 72,875 | 117.8 K to 72.9 K (-38.13 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 6,772 | 0 | 81,380 | 88.2 K to 81.4 K (-7.68 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 6,772 | 0 | 81,380 | 88.2 K to 81.4 K (-7.68 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 360,561 | 0 | 3,729,141 | 4.1 M to 3.7 M (-8.82 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | J | 0.00 | 360,561 | 0 | 3,729,141 | 4.1 M to 3.7 M (-8.82 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 44,903 | 0 | 72,875 | 117.8 K to 72.9 K (-38.13 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 44,903 | 0 | 72,875 | 117.8 K to 72.9 K (-38.13 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 6,772 | 0 | 81,380 | 88.2 K to 81.4 K (-7.68 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 6,772 | 0 | 81,380 | 88.2 K to 81.4 K (-7.68 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 360,561 | 0 | 3,729,141 | 4.1 M to 3.7 M (-8.82 %) |
May 29 2020 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | J | 0.00 | 360,561 | 0 | 3,729,141 | 4.1 M to 3.7 M (-8.82 %) |
Mar 05 2020 | SNTA | MADRIGAL PHARMACEU ... | Lynch Brian Joseph | SVP and General Cou ... | Option Exercise | A | 91.79 | 32,000 | 2,937,280 | 32,000 | |
Mar 05 2020 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Option Exercise | A | 91.79 | 50,000 | 4,589,500 | 50,000 | |
Mar 05 2020 | SNTA | MADRIGAL PHARMACEU ... | Taub Rebecca | Pres., R&D, and CMO | Option Exercise | A | 91.79 | 44,000 | 4,038,760 | 44,000 | |
Mar 05 2020 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Option Exercise | A | 91.79 | 32,000 | 2,937,280 | 32,000 | |
Feb 26 2020 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Sell | S | 131.60 | 10,000 | 1,316,000 | 20,000 | 30 K to 20 K (-33.33 %) |
Feb 26 2020 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Sell | S | 112.54 | 20,000 | 2,250,800 | 0 | 20 K to 0 (-100.00 %) |
Dec 13 2019 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | S | 105.47 | 25,320 | 2,670,500 | 88,152 | 113.5 K to 88.2 K (-22.31 %) |
Dec 13 2019 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | 10% Owner | Sell | S | 105.47 | 1,174,680 | 123,893,500 | 4,089,702 | 5.3 M to 4.1 M (-22.31 %) |
Dec 13 2019 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | S | 105.47 | 25,320 | 2,670,500 | 88,152 | 113.5 K to 88.2 K (-22.31 %) |
Dec 13 2019 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | S | 105.47 | 1,174,680 | 123,893,500 | 4,089,702 | 5.3 M to 4.1 M (-22.31 %) |
Jul 11 2019 | SNTA | MADRIGAL PHARMACEU ... | Taub Rebecca | President of R&D | Option Exercise | A | 101.30 | 8,000 | 810,400 | 8,000 | |
Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 100.45 | 10,000 | 1,004,500 | 10,000 | |
Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 100.45 | 10,000 | 1,004,500 | 10,000 | |
Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | Daly James M | Director | Option Exercise | A | 100.45 | 20,000 | 2,009,000 | 20,000 | |
Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Option Exercise | A | 100.45 | 10,000 | 1,004,500 | 10,000 | |
Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | Gollust Keith R | Director | Option Exercise | A | 100.45 | 10,000 | 1,004,500 | 10,000 | |
Jul 01 2019 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Option Exercise | A | 100.45 | 10,000 | 1,004,500 | 10,000 | |
Mar 11 2019 | SNTA | MADRIGAL PHARMACEU ... | Taub Rebecca | Chief Medical Offic ... | Option Exercise | A | 127.96 | 38,000 | 4,862,480 | 38,000 | |
Mar 11 2019 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Option Exercise | A | 127.96 | 50,000 | 6,398,000 | 50,000 | |
Mar 11 2019 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Option Exercise | A | 127.96 | 28,000 | 3,582,880 | 28,000 | |
Nov 23 2018 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Buy | P | 117.88 | 4,000 | 471,520 | 161,128 | 157.1 K to 161.1 K (+2.55 %) |
Nov 19 2018 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Buy | P | 124.00 | 4,000 | 496,000 | 157,128 | 153.1 K to 157.1 K (+2.61 %) |
Nov 19 2018 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Buy | P | 125.00 | 900 | 112,500 | 298,067 | 297.2 K to 298.1 K (+0.30 %) |
Nov 19 2018 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Buy | P | 124.57 | 1,000 | 124,570 | 297,167 | 296.2 K to 297.2 K (+0.34 %) |
Nov 19 2018 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Buy | P | 123.17 | 100 | 12,317 | 296,167 | 296.1 K to 296.2 K (+0.03 %) |
Sep 19 2018 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Option Exercise | M | 9.45 | 20,000 | 189,000 | 0 | |
Sep 19 2018 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Buy | M | 9.45 | 20,000 | 189,000 | 20,000 | 0 to 20 K |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | Gollust Keith R | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Jun 21 2018 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 303.79 | 10,000 | 3,037,900 | 10,000 | |
Jun 13 2018 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Option Exercise | M | 61.60 | 2,734 | 168,414 | 1,640 | |
Jun 13 2018 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Option Exercise | M | 99.75 | 5,223 | 520,994 | 1,205 | |
Jun 13 2018 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Sell | S | 287.46 | 10,099 | 2,903,059 | 41,668 | 51.8 K to 41.7 K (-19.51 %) |
Jun 13 2018 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Buy | M | 61.60 | 2,734 | 168,414 | 51,767 | 49 K to 51.8 K (+5.58 %) |
Jun 13 2018 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Buy | M | 99.75 | 5,223 | 520,994 | 49,033 | 43.8 K to 49 K (+11.92 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Buy | S | 287.46 | 5,908 | 1,698,314 | 113,472 | 107.6 K to 113.5 K (+5.49 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Buy | S | 287.46 | 5,908 | 1,698,314 | 113,472 | 107.6 K to 113.5 K (+5.49 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | S | 287.46 | 274,092 | 78,790,486 | 5,264,382 | 5.5 M to 5.3 M (-4.95 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Sell | S | 287.46 | 274,092 | 78,790,486 | 5,264,382 | 5.5 M to 5.3 M (-4.95 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Sell | S | 287.46 | 73,526 | 21,135,784 | 655,540 | 729.1 K to 655.5 K (-10.08 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Sell | S | 287.46 | 73,526 | 21,135,784 | 655,540 | 729.1 K to 655.5 K (-10.08 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | Taub Rebecca | Chief Medical Offic ... | Buy | S | 287.46 | 73,526 | 21,135,784 | 655,540 | 582 K to 655.5 K (+12.63 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | Taub Rebecca | Chief Medical Offic ... | Buy | S | 287.46 | 73,526 | 21,135,784 | 655,540 | 582 K to 655.5 K (+12.63 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | Director | Sell | S | 287.46 | 5,908 | 1,698,314 | 113,472 | 119.4 K to 113.5 K (-4.95 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | Director | Sell | S | 287.46 | 5,908 | 1,698,314 | 113,472 | 119.4 K to 113.5 K (-4.95 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | Director | Sell | S | 287.46 | 274,092 | 78,790,486 | 5,264,382 | 5.5 M to 5.3 M (-4.95 %) |
Jun 12 2018 | SNTA | MADRIGAL PHARMACEU ... | BAY CITY CAPITAL LLC | Director | Sell | S | 287.46 | 274,092 | 78,790,486 | 5,264,382 | 5.5 M to 5.3 M (-4.95 %) |
Mar 05 2018 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Option Exercise | A | 124.45 | 28,000 | 3,484,600 | 28,000 | |
Mar 05 2018 | SNTA | MADRIGAL PHARMACEU ... | Taub Rebecca | Chief Medical Offic ... | Option Exercise | A | 124.45 | 38,000 | 4,729,100 | 38,000 | |
Mar 05 2018 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Option Exercise | A | 124.45 | 50,000 | 6,222,500 | 50,000 | |
Aug 24 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.25 | 7 | 114 | 9,100 | 9.1 K to 9.1 K (+0.08 %) |
Aug 24 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.12 | 1,793 | 28,903 | 9,093 | 7.3 K to 9.1 K (+24.56 %) |
Aug 24 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.11 | 100 | 1,611 | 7,300 | 7.2 K to 7.3 K (+1.39 %) |
Aug 24 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.08 | 100 | 1,608 | 7,200 | 7.1 K to 7.2 K (+1.41 %) |
Aug 23 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.14 | 127 | 2,050 | 7,100 | 7 K to 7.1 K (+1.82 %) |
Aug 23 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.12 | 2,944 | 47,457 | 6,973 | 4 K to 7 K (+73.07 %) |
Aug 23 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.10 | 389 | 6,263 | 4,029 | 3.6 K to 4 K (+10.69 %) |
Aug 23 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.99 | 90 | 1,439 | 3,640 | 3.6 K to 3.6 K (+2.54 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.09 | 590 | 9,493 | 3,550 | 3 K to 3.6 K (+19.93 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.07 | 440 | 7,071 | 2,960 | 2.5 K to 3 K (+17.46 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.04 | 210 | 3,368 | 2,520 | 2.3 K to 2.5 K (+9.09 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 16.02 | 200 | 3,204 | 2,310 | 2.1 K to 2.3 K (+9.48 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.93 | 200 | 3,186 | 2,110 | 1.9 K to 2.1 K (+10.47 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.90 | 10 | 159 | 1,910 | 1.9 K to 1.9 K (+0.53 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.80 | 400 | 6,320 | 1,900 | 1.5 K to 1.9 K (+26.67 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.79 | 200 | 3,158 | 1,500 | 1.3 K to 1.5 K (+15.38 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.77 | 200 | 3,154 | 1,300 | 1.1 K to 1.3 K (+18.18 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.72 | 100 | 1,572 | 1,100 | 1,000 to 1.1 K (+10.00 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.70 | 100 | 1,570 | 1,000 | 900 to 1,000 (+11.11 %) |
Aug 22 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Buy | P | 15.67 | 900 | 14,103 | 900 | 0 to 900 |
Jun 30 2017 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Option Exercise | A | 16.46 | 10,000 | 164,600 | 10,000 | |
Jun 30 2017 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 16.46 | 10,000 | 164,600 | 10,000 | |
Jun 30 2017 | SNTA | MADRIGAL PHARMACEU ... | Gollust Keith R | Director | Option Exercise | A | 16.46 | 10,000 | 164,600 | 10,000 | |
Jun 30 2017 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Option Exercise | A | 16.46 | 10,000 | 164,600 | 10,000 | |
Jun 30 2017 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 16.46 | 10,000 | 164,600 | 10,000 | |
Mar 06 2017 | SNTA | MADRIGAL PHARMACEU ... | Taub Rebecca | Chief Medical Offic ... | Option Exercise | A | 15.80 | 37,300 | 589,340 | 37,300 | |
Mar 06 2017 | SNTA | MADRIGAL PHARMACEU ... | Schneebaum Marc R | Chief Financial Off ... | Option Exercise | A | 15.80 | 27,300 | 431,340 | 27,300 | |
Mar 06 2017 | SNTA | MADRIGAL PHARMACEU ... | FRIEDMAN PAUL A | Chief Executive Off ... | Option Exercise | A | 15.80 | 49,600 | 783,680 | 49,600 | |
Nov 21 2016 | SNTA | MADRIGAL PHARMACEU ... | Levy Richard S | Director | Option Exercise | A | 7.36 | 20,000 | 147,200 | 20,000 | |
Oct 24 2016 | SNTA | MADRIGAL PHARMACEU ... | CRAVES FRED B | Director | Option Exercise | A | 12.01 | 20,000 | 240,200 | 20,000 | |
Oct 24 2016 | SNTA | MADRIGAL PHARMACEU ... | Gollust Keith R | Director | Option Exercise | A | 12.01 | 20,000 | 240,200 | 20,000 | |
Oct 24 2016 | SNTA | MADRIGAL PHARMACEU ... | BATE KENNETH | Director | Option Exercise | A | 12.01 | 20,000 | 240,200 | 20,000 | |
Oct 24 2016 | SNTA | MADRIGAL PHARMACEU ... | MILLIGAN DAVID V | Director | Option Exercise | A | 12.01 | 20,000 | 240,200 | 20,000 | |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | CRAVES FRED B | Director | Grant | A | 0.00 | 119,380 | 0 | 119,380 | 0 to 119.4 K |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | CRAVES FRED B | Director | Grant | A | 0.00 | 5,538,474 | 0 | 5,538,474 | 0 to 5.5 M |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | CRAVES FRED B | Director | Grant | A | 0.00 | 296,067 | 0 | 296,067 | 0 to 296.1 K |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | Schneebaum Marc R | Chief Financial Off ... | Option Exercise | A | 9.45 | 91,876 | 868,228 | 91,876 | |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | Schneebaum Marc R | Chief Financial Off ... | Grant | A | 0.00 | 22,969 | 0 | 42,277 | 19.3 K to 42.3 K (+118.96 %) |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | FRIEDMAN PAUL A | Chief Executive Off ... | Option Exercise | A | 9.45 | 287,115 | 2,713,237 | 287,115 | |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | FRIEDMAN PAUL A | Chief Executive Off ... | Grant | A | 0.00 | 729,066 | 0 | 729,066 | 0 to 729.1 K |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | FRIEDMAN PAUL A | Chief Executive Off ... | Grant | A | 0.00 | 143,557 | 0 | 143,703 | 146 to 143.7 K (+98,326.71 %) |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | FRIEDMAN PAUL A | Chief Executive Off ... | Grant | A | 0.00 | 146 | 0 | 146 | 0 to 146 |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | Taub Rebecca | Chief Medical Offic ... | Option Exercise | A | 9.45 | 143,557 | 1,356,614 | 143,557 | |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | Taub Rebecca | Chief Medical Offic ... | Grant | A | 0.00 | 28,740 | 0 | 432,872 | 404.1 K to 432.9 K (+7.11 %) |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | Taub Rebecca | Chief Medical Offic ... | Grant | A | 0.00 | 404,132 | 0 | 404,132 | 0 to 404.1 K |
Jul 26 2016 | SNTA | SYNTA PHARMACEUTIC ... | Taub Rebecca | Chief Medical Offic ... | Grant | A | 0.00 | 729,066 | 0 | 729,066 | 0 to 729.1 K |
Jul 22 2016 | SNTA | SYNTA PHARMACEUTIC ... | Schor Chen | Former President an ... | Payment of Exercise | F | 9.48 | 14,250 | 135,090 | 37,178 | 51.4 K to 37.2 K (-27.71 %) |
Jul 22 2016 | SNTA | SYNTA PHARMACEUTIC ... | Schor Chen | Former President an ... | Grant | A | 0.00 | 42,857 | 0 | 51,428 | 8.6 K to 51.4 K (+500.02 %) |
Jul 22 2016 | SNTA | SYNTA PHARMACEUTIC ... | Schneebaum Marc R | SVP and CFO | Payment of Exercise | F | 9.48 | 8,548 | 81,035 | 19,308 | 27.9 K to 19.3 K (-30.69 %) |
Jul 22 2016 | SNTA | SYNTA PHARMACEUTIC ... | Schneebaum Marc R | SVP and CFO | Grant | A | 0.00 | 25,714 | 0 | 27,856 | 2.1 K to 27.9 K (+1,200.47 %) |
Jul 22 2016 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | Former SVP, Gen. Co ... | Payment of Exercise | F | 9.48 | 8,550 | 81,054 | 17,730 | 26.3 K to 17.7 K (-32.53 %) |
Jul 22 2016 | SNTA | SYNTA PHARMACEUTIC ... | Rieder Wendy E | Former SVP, Gen. Co ... | Grant | A | 0.00 | 25,714 | 0 | 26,280 | 566 to 26.3 K (+4,543.11 %) |
Jan 05 2016 | SNTA | SYNTA PHARMACEUTIC ... | Morenstein Scott D | Director | Grant | A | 0.00 | 17,857 | 0 | 17,857 | 0 to 17.9 K |